Interesting Images18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1–Positive Non–Small Cell Lung CancerDejust, Sébastien MD*; Moubtakir, Abdenasser MD*; Prevost, Alain MD†; El Farsaoui, Khadija MD*; Morland, David MD, MSc*,‡,§Author Information From the *Unité de Médecine Nucléaire †Département d'Oncologie Médicale, Institut Godinot ‡Laboratoire de Biophysique, UFR de Médecine §CRESTIC Centre de Recherche en Sciences et Technologies de l'Information et de la Communication, EA 3804, Université de Reims-Champagne Ardenne, Reims, France. Received for publication October 30, 2019; revision accepted October 30, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Sébastien Dejust, MD, Service de Médecine Nucléaire, Institut Godinot, 1 Rue du Général Koenig, 51100 Reims, France. E-mail: firstname.lastname@example.org. Online date: January 30, 2019 Clinical Nuclear Medicine: March 2020 - Volume 45 - Issue 3 - p 209-210 doi: 10.1097/RLU.0000000000002912 Buy Metrics Abstract ROS-1–positive non–small cell lung cancers (NSCLCs) are rare (approximately 1% of all NSCLCs) and require a first-line treatment by crizotinib. Crizotinib resistance is frequent within the first 12 months of treatment. Lorlatinib is a novel tyrosine kinase inhibitor of ROS-1 recently indicated for metastatic or locally advanced crizotinib-resistant NSCLC. We report the use of lorlatinib as second-line with a complete tumoral response after only 3 months of treatment. This case shows the major role of 18F-FDG PET/CT in treatment evaluation and monitoring targeted therapy in metastatic NSCLC. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.